



## Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

February 26, 2024

**- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion -**

BOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- [Inozyme Pharma, Inc.](#) (Nasdaq: INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the Company's chief executive officer and chairman of the board, will participate in an Orphan Bone & Neuromuscular Diseases panel presentation at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024, from 9:10-10:10am ET.

A live webcast of the panel presentation can be accessed from the [Investor Relations](#) section of Inozyme's website under [events](#), where a replay of the event will also be available for a limited time.

### **About Inozyme Pharma**

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Inozyme is developing INZ-701, an enzyme replacement therapy, to treat pathologic mineralization and intimal proliferation and improve morbidity and mortality in these severe diseases. INZ-701 is currently in clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

For more information, please visit [www.inozyme.com](http://www.inozyme.com) and follow us on [LinkedIn](#), [X](#) (formerly [Twitter](#)), and [Facebook](#).

### **Contacts**

Investors:

Inozyme Pharma

Stefan Riley, Director of IR and Corporate Communications

(857) 330-8871

[stefan.riley@inozyme.com](mailto:stefan.riley@inozyme.com)

Media:

SmithSolve

Matt Pera

(973) 886-9150

[matt.pera@smithsolve.com](mailto:matt.pera@smithsolve.com)